Semaglutide vs Tirzepatide:
Compare GLP-1 Weight Loss Programs

Clinical Science

Semaglutide vs. Tirzepatide: Understanding the Clinical Evidence Behind GLP-1 Weight Loss Medications

When comparing GLP-1 weight loss medications, it is essential to understand the clinical trial evidence that underpins each option. Semaglutide and tirzepatide are the two most effective pharmaceutical treatments for chronic weight management currently available through telehealth platforms like Open Water Rx. Both medications work by mimicking natural gut hormones that regulate appetite, slow gastric emptying, and signal satiety to the brain, but they differ in their mechanisms, efficacy profiles, and clinical trial outcomes.

Semaglutide is a GLP-1 receptor agonist that was originally developed for type 2 diabetes management under the brand name Ozempic and later approved for chronic weight management as Wegovy. The landmark STEP 1 clinical trial, published in the New England Journal of Medicine in 2021, randomized 1,961 adults with overweight or obesity to receive either semaglutide 2.4 mg weekly or placebo. After 68 weeks, participants in the semaglutide group achieved an average body weight reduction of 14.9 percent, with approximately one-third of participants losing 20 percent or more of their initial body weight. The STEP 4 trial demonstrated that continuing semaglutide maintained weight loss, while discontinuing led to gradual regain — highlighting the importance of ongoing treatment.

Tirzepatide represents the next generation of incretin-based therapy. Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults without diabetes and randomized them to tirzepatide 5 mg, 10 mg, 15 mg weekly, or placebo. After 72 weeks, the highest dose group achieved an unprecedented average body weight reduction of 22.5 percent — the highest ever recorded in a pharmaceutical weight loss study. The SURMOUNT-3 trial, which included an intensive lifestyle intervention lead-in period, reported even greater results with tirzepatide following diet and exercise.

How to choose between them? Your independent licensed medical provider will make this recommendation based on your complete health profile, not on efficacy alone. Factors considered include your baseline weight, BMI, presence of type 2 diabetes or prediabetes, cardiovascular history, gastrointestinal tolerance, prior medication experience, personal preferences regarding injection frequency, and cost considerations. Tirzepatide's higher efficacy comes with a higher price point ($339/month vs. $249/month for semaglutide). Some patients may start with semaglutide and transition to tirzepatide later if additional weight loss is needed. Others may begin with tirzepatide if their provider determines they are good candidates and the higher efficacy justifies the higher cost. There is no universally "better" option — only the option that is clinically appropriate for you. See FAQ for more on choosing.